a Department of Oncology and Medicine , University of Calgary and Tom Baker Cancer Centre , Calgary , Alberta , Canada.
b Department of Medicine , University of Alberta and Cross Cancer Institute , Edmonton , Alberta , Canada.
Leuk Lymphoma. 2019 Jan;60(1):133-141. doi: 10.1080/10428194.2018.1473576. Epub 2018 Jul 3.
Although chemoimmunotherapy improves outcomes for patients with follicular lymphoma (FL), approximately 20% of patients experience early disease progression within two years of treatment and subsequently poor median survival. We conducted a retrospective study to evaluate survival rates of patients with early relapse who were treated with or without autologous transplantation. Of 517 patients with FL and who received chemoimmunotherapy, 152 relapsed and survived a minimum of four months after progression, including 84 (55.3%) with early relapse ≤2 years following initial therapy and 68 (44.7%) with later relapse. Five-year survival was superior for patients who received autologous transplantation compared to non-transplanted patients within the early relapse group (85.4% vs 57.9%, p = .001), but not within the late relapse group (p = .64). Given the limitations of a retrospective study, our study may suggest that the use of autologous transplantation for FL patients who relapse within two years of initial chemoimmunotherapy is associated with improved survival.
虽然化疗免疫疗法改善了滤泡性淋巴瘤（FL）患者的预后，但约 20%的患者在治疗后两年内出现早期疾病进展，随后中位生存期较差。我们进行了一项回顾性研究，以评估接受或未接受自体移植的早期复发患者的生存率。在接受化疗免疫疗法的 517 例 FL 患者中，有 152 例复发并在进展后至少存活了 4 个月，其中 84 例（55.3%）在初始治疗后 2 年内发生早期复发≤2 年，68 例（44.7%）发生晚期复发。与未接受移植的患者相比，早期复发组接受自体移植的患者 5 年生存率更高（85.4%比 57.9%，p=0.001），但晚期复发组无差异（p=0.64）。鉴于回顾性研究的局限性，我们的研究可能表明，对于初始化疗免疫治疗后 2 年内复发的 FL 患者，使用自体移植与生存改善相关。
